These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9336992)

  • 1. Characteristics of clients with schizophrenia who express certainty or uncertainty about continuing treatment with depot neuroleptic medication.
    Bunn MH; O'Connor AM; Tansey MS; Jones BD; Stinson LE
    Arch Psychiatr Nurs; 1997 Oct; 11(5):238-48. PubMed ID: 9336992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of client decision-making instruments in the context of psychiatry.
    Bunn H; O'Connor A
    Can J Nurs Res; 1996; 28(3):13-27. PubMed ID: 8997937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nurse's role in neuroleptic medications.
    Chapman T
    J Psychosoc Nurs Ment Health Serv; 1991 Jun; 29(6):6-8. PubMed ID: 1681099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The subjective experiences of people who regularly receive depot neuroleptic medication in the community.
    Phillips L; McCann E
    J Psychiatr Ment Health Nurs; 2007 Sep; 14(6):578-86. PubMed ID: 17718731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative symptoms of schizophrenia and compliance with medication.
    Tattan TM; Creed FH
    Schizophr Bull; 2001; 27(1):149-55. PubMed ID: 11215543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia.
    Rogers A; Day JC; Williams B; Randall F; Wood P; Healy D; Bentall RP
    Soc Sci Med; 1998 Nov; 47(9):1313-23. PubMed ID: 9783874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight.
    Garavan J; Browne S; Gervin M; Lane A; Larkin C; O'Callaghan E
    Compr Psychiatry; 1998; 39(4):215-9. PubMed ID: 9675506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen.
    Weiden P; Rapkin B; Zygmunt A; Mott T; Goldman D; Frances A
    Psychiatr Serv; 1995 Oct; 46(10):1049-54. PubMed ID: 8829787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing medication use in schizophrenic patients.
    Diamond RJ
    J Clin Psychiatry; 1983 Jun; 44(6 Pt 2):7-14. PubMed ID: 6133855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the community mental health nurse in the administration of depot neuroleptic medication: 'not just the needle nurse!'.
    Muir-Cochrane EC
    Int J Nurs Pract; 1998 Dec; 4(4):254-60. PubMed ID: 10095520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician.
    Franz M; Ranger J; Hanewald B; Gallhofer B; Lay B
    Pharmacopsychiatry; 2012 Nov; 45(7):261-8. PubMed ID: 22648306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic.
    Pan PC; Tantam D
    Acta Psychiatr Scand; 1989 Jun; 79(6):564-70. PubMed ID: 2569803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
    Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
    J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire.
    Kampman O; Lehtinen K; Lassila V; Leinonen E; Poutanen O; Koivisto A
    Schizophr Res; 2000 Oct; 45(3):223-34. PubMed ID: 11042440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial.
    Noordraven EL; Wierdsma AI; Blanken P; Bloemendaal AFT; Mulder CL
    BMC Psychiatry; 2018 May; 18(1):144. PubMed ID: 29793451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicine taking decisions: schizophrenia in comparison to asthma and epilepsy.
    Marland GR; Cash K
    J Psychiatr Ment Health Nurs; 2005 Apr; 12(2):163-72. PubMed ID: 15788033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosocial and socio-demographic correlates of medication compliance among people with schizophrenia.
    Tsang HW; Fung KM; Corrigan PW
    J Behav Ther Exp Psychiatry; 2009 Mar; 40(1):3-14. PubMed ID: 18417098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.